19:25 , Jul 5, 2018 |  BC Week In Review  |  Clinical News

Alkermes' Aristada Initio approved for schizophrenia

FDA approved Aristada Initio aripiprazole lauroxil from Alkermes plc (NASDAQ:ALKS) in combination with oral aripiprazole to initiate treatment of schizophrenia in adults. The company expects to launch the product mid-July. Aristada Initio is an extended-release injectable...
19:21 , Jul 2, 2018 |  BC Extra  |  Company News

New dose regimen for Alkermes' aripiprazole approved

Alkermes plc (NASDAQ:ALKS) said FDA approved Aristada Initio aripiprazole lauroxil in combination with oral aripiprazole for adult schizophrenia patients initiating treatment with Aristada. Aristada previously required three weeks of oral aripiprazole supplementation following the first...
18:29 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

CHMP recommendations include Aimovig, orphan candidates

Among a host of positive recommendations announced on June 1, EMA's CHMP backed approval of migraine therapy Aimovig erenumab and Orphan Drug designees Tegsedi inotersen for hereditary transthyretin (TTR) amyloidosis and Myalepta metreleptin for leptin...